BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

...of the hopes, not to mention hype, associated with this vaccine. William Haseltine, who founded Human Genome Sciences...
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

...other companies; and Haseltine was a Harvard Medical School professor and chairman and CEO of Human Genome Sciences Inc....
BioCentury | Aug 1, 2016
Strategy

Bug battle plan

...GSK consolidated its U.S. vaccine R&D activities into a facility in Maryland that formerly housed Human Genome Sciences Inc....
BioCentury | Mar 14, 2016
Company News

Five Prime, GlaxoSmithKline deal

...develop and commercialize cancer candidate FP-1039 . The original deal was between Five Prime and Human Genome Sciences Inc....
BioCentury | Mar 11, 2016
Company News

GSK ending deal for Five Prime's FP-1039

...presented at American Society of Clinical Oncology meeting in June. In 2011, Five Prime granted Human Genome Sciences Inc....
BioCentury | Nov 16, 2015
Product Development

On SLE's trail

...became the first drug approved for SLE in more than 50 years. The drug's originator, Human Genome Sciences Inc....
BioCentury | Aug 10, 2015
Finance

And then there were two

...been acquired after achieving varying degrees of success, including CuraGen Corp. (bought for $93.5 million), Human Genome Sciences Inc....
BioCentury | Aug 18, 2014
Company News

Inotek management update

...Autoimmune Hired: David Southwell as president, CEO and a director, formerly EVP and CFO of Human Genome Sciences Inc....
BioCentury | May 19, 2014
Clinical News

Darapladib: Phase III data

...AD) and diabetic macular edema (DME). The pharma gained darapladib through its 2012 acquisition of Human Genome Sciences Inc....
BioCentury | May 14, 2014
Clinical News

GSK's darapladib misses in Phase III ACS trial

...lipoprotein-associated phospholipase A2 ( PLA2G7 ; PAFAH ; Lp-PLA2 ) through its 2012 acquisition of Human Genome Sciences Inc....
Items per page:
1 - 10 of 1018
BioCentury | May 18, 2020
Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

...of the hopes, not to mention hype, associated with this vaccine. William Haseltine, who founded Human Genome Sciences...
BioCentury | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

...other companies; and Haseltine was a Harvard Medical School professor and chairman and CEO of Human Genome Sciences Inc....
BioCentury | Aug 1, 2016
Strategy

Bug battle plan

...GSK consolidated its U.S. vaccine R&D activities into a facility in Maryland that formerly housed Human Genome Sciences Inc....
BioCentury | Mar 14, 2016
Company News

Five Prime, GlaxoSmithKline deal

...develop and commercialize cancer candidate FP-1039 . The original deal was between Five Prime and Human Genome Sciences Inc....
BioCentury | Mar 11, 2016
Company News

GSK ending deal for Five Prime's FP-1039

...presented at American Society of Clinical Oncology meeting in June. In 2011, Five Prime granted Human Genome Sciences Inc....
BioCentury | Nov 16, 2015
Product Development

On SLE's trail

...became the first drug approved for SLE in more than 50 years. The drug's originator, Human Genome Sciences Inc....
BioCentury | Aug 10, 2015
Finance

And then there were two

...been acquired after achieving varying degrees of success, including CuraGen Corp. (bought for $93.5 million), Human Genome Sciences Inc....
BioCentury | Aug 18, 2014
Company News

Inotek management update

...Autoimmune Hired: David Southwell as president, CEO and a director, formerly EVP and CFO of Human Genome Sciences Inc....
BioCentury | May 19, 2014
Clinical News

Darapladib: Phase III data

...AD) and diabetic macular edema (DME). The pharma gained darapladib through its 2012 acquisition of Human Genome Sciences Inc....
BioCentury | May 14, 2014
Clinical News

GSK's darapladib misses in Phase III ACS trial

...lipoprotein-associated phospholipase A2 ( PLA2G7 ; PAFAH ; Lp-PLA2 ) through its 2012 acquisition of Human Genome Sciences Inc....
Items per page:
1 - 10 of 1018